KSQ Therapeutics has dosed the first patient in a Phase 1/2 trial evaluating KSQ-004EX, a novel CRISPR-engineered tumor infiltrating lymphocyte therapy, for advanced solid tumors.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.